Literature DB >> 8045024

Benefits and risks of emerging genetic technologies: the need for regulation.

N A Holtzman1.   

Abstract

Efforts to localize human genes to specific chromosomes and then to identify these genes and their role in specific diseases are increasing. These developments will expand the repertoire of genetic tests that are claimed to be predictive of future disease in the person being tested (pre-symptomatic tests) or in future offspring of those being tested (tests for reproductive options). In single-gene (mendelian) disorders, such tests may fail to detect all of the alleles capable of causing disease. In multifactorial disorders, positive results of tests for specific alleles will not always predict future disease because the other necessary factors may be absent. Policies are already in place to provide safe and effective clinical laboratory tests and interventions for subjects with positive test results, and to assure the quality of the laboratories performing such tests, but are not widely known or enforced for genetic tests.

Entities:  

Keywords:  Genetics and Reproduction; Human Genome Project

Mesh:

Year:  1994        PMID: 8045024

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Scope of definitions of genetic testing: evidence from a EuroGentest survey.

Authors:  Jorge Pinto-Basto; Bárbara Guimarães; Elina Rantanen; Poupak Javaher; Irma Nippert; Jean-Jacques Cassiman; Helena Kääriäinen; Ulf Kristoffersson; Jörg Schmidtke; Jorge Sequeiros
Journal:  J Community Genet       Date:  2010-03-16

Review 2.  Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine.

Authors:  R Mayeux; N Schupf
Journal:  Am J Public Health       Date:  1995-09       Impact factor: 9.308

3.  A sociobehavioural perspective on genetic testing and counselling for heritable breast, ovarian and colon cancer.

Authors:  K G Macdonald; B Doan; M Kelner; K M Taylor
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.